I. A. McNeish

This study identifies HMOX1-expressing omental macrophages as a therapeutic target and biomarker for poor prognosis ovarian high-grade serous carcinoma.

This study identifies ARF6 as a critical vulnerability in PTEN-deficient ovarian cancer, showing its role in integrin-dependent invasion and its inverse association with patient outcomes.

This study identifies centrosome amplification as a common and heterogeneous feature in HGSOC, linked to CIN and treatment resistance.

This study shows that PARPi treatment can reverse RAD51C promoter methylation and restore expression in a high-grade serous ovarian cancer model, while maintaining platinum sensitivity.

This study investigates platinum resistance in high grade serous ovarian cancer by analyzing transcriptomic features and evolutionary trajectories in resistant models.

This study identifies large structural variants as a significant source of homologous repair deficiency in high-grade serous ovarian carcinoma, beyond known SNVs and indels at BRCA1/2.

This study identifies copy-number signatures in ovarian cancer and links them to mutational processes, showing that most cases involve multiple processes, suggesting therapeutic challenges.